Amphiphilic Alginate-Oleic Acid Nanoparticles for Higher Drug Loading

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing nanoparticle delivery systems face challenges in efficiently incorporating biologically active agents due to limited loading capacity and slow incorporation times, which hinders their practical and commercial utility, and there is a need for an efficient process to manufacture nanoparticles for delivering such agents.

Innovation Solution

The development of amphiphilic alginate-oleic acid (AGO) macromolecules, composed of alginate and oleic acid linked with a spacer, which exhibit self-assembly behavior to form nanoparticles with clinically-accessible molecular size, providing excellent structural stability and biocompatibility, allowing for the encapsulation of single or multiple active agents.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Quantity of substance

If conventional nanoparticles are used for delivery, then the delivery system can be formed, but the loading capacity and incorporation speed of biologically active agents are limited

Engineering Contradiction:

Improveloading capacity of biologically active agentVSAvoidincorporation speed of biologically active agent

Core Design Contradiction:

Quantity of substanceVSProductivity

Solution Approach 1:

The patent employs a composite nanoparticle structure consisting of chitosan (hydrophilic) and oleic acid (hydrophobic) components. This composite material enables simultaneous incorporation of both hydrophilic and hydrophobic biologically active agents, significantly increasing loading capacity. The dual-component system creates distinct phases for different types of agents, solving the limitation of conventional single-material nanoparticles.

Inventive Principle:

Principle #40Composite materials

Solution Approach 2:

The patent utilizes pH-responsive parameter changes to control the incorporation and release of biologically active agents. The chitosan-oleic acid complex exhibits pH-dependent solubility and structural changes, allowing rapid incorporation at acidic pH and controlled release at physiological pH. This parameter-based control dramatically improves incorporation speed compared to passive diffusion methods.

Inventive Principle:

Principle #35Parameter changes

2Adaptability or versatility

If amphiphilic modification is applied to alginate, then self-assembly ability and drug encapsulation capability are enhanced, but the molecular weight must be controlled below renal clearance threshold

Engineering Contradiction:

Improveself-assembly ability and drug encapsulation capabilityVSAvoidmolecular weight of alginate

Core Design Contradiction:

Adaptability or versatilityVSWeight of moving object

Solution Approach 1:

The patent segments the large alginate molecule into smaller oligosaccharide units through controlled degradation, reducing molecular weight below the renal clearance threshold (50-70 kDa). This segmentation maintains the essential functional groups for amphiphilic modification while enabling renal clearance of the modified alginate, thus achieving both self-assembly capability and metabolic clearance.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent modifies the molecular weight parameter of alginate through controlled degradation to fall within the renal clearance range. This parameter change enables the amphiphilically modified alginate to be cleared by kidneys after drug delivery, improving safety profile while maintaining the self-assembly and encapsulation properties required for functionality.

Inventive Principle:

Principle #35Parameter changes

3Ease of manufacture

If commercial sodium alginate is used without treatment, then the material is readily available, but the molecular weight is too high and distribution is wide for nanoparticle synthesis

Engineering Contradiction:

Improveavailability of materialVSAvoidmolecular weight control and distribution

Core Design Contradiction:

Ease of manufactureVSManufacturing precision

Solution Approach 1:

The patent applies preliminary controlled degradation treatment to commercial sodium alginate before nanoparticle synthesis. This preliminary action reduces the molecular weight and narrows the distribution, creating a more suitable substrate for consistent nanoparticle formation. By preparing the alginate in advance with controlled properties, the subsequent nanoparticle synthesis achieves better precision and reproducibility.

Inventive Principle:

Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

AGO nanoparticles offer a stable and biocompatible delivery system for drugs or biological agents, enabling efficient encapsulation and controlled release, with potential for anti-cancer activity and multifunctional biomedical applications.

Implementation Method 1

the AGO macromolecule has self-assembly behavior in aqueous solution to form nanoparticles

Methodology Applied

Scientific EffectSelf-assembly: Self-Assembly

Data Source

PatentUS12508324B2Amphiphilic alginate-oleic acid macromolecules and process for preparation thereof

Publication Date: 2025.12.30 NUECOLOGY BIOMEDICAL INC

AI summary

The present invention provides a new type of hydrophobically -modified sodium alginate, which is synthesized by alginate and oleic acid linked with a spacer. The AGO macromolecule as obtained therefrom is amphiphilic and has clinically-accessible molecular size, and anti- cancer activity. The AGO nanoparticle formed therefrom shows excellent structural stability, colloidal stability, and biocompatibility in-vitro and in-vivo, and is expected to be useful in biomedical area, for example, used as a drug delivery system.